-
[Angiogenesis and tumor progression in melanoma].
Recenti Prog Med. 2000 Nov;91(11):581-7
PMID: 11125952
-
Angiogenesis in melanoma.
Semin Oncol. 2007 Dec;34(6):555-65
PMID: 18083379
-
Thalidomide influences growth and vasculogenic mimicry channel formation in melanoma.
J Exp Clin Cancer Res. 2008 Nov 04;27:60
PMID: 18983651
-
Matrix metalloproteinase inhibitors and cancer: trials and tribulations.
Science. 2002 Mar 29;295(5564):2387-92
PMID: 11923519
-
High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma.
Clin Cancer Res. 2005 Jul 15;11(14):5158-66
PMID: 16033831
-
A phase I biological and pharmacologic study of the heparanase inhibitor PI-88 in patients with advanced solid tumors.
Clin Cancer Res. 2006 Sep 15;12(18):5471-80
PMID: 17000682
-
Matriptase activates stromelysin (MMP-3) and promotes tumor growth and angiogenesis.
Cancer Sci. 2006 Dec;97(12):1327-34
PMID: 16999819
-
The history of the angiogenic switch concept.
Leukemia. 2007 Jan;21(1):44-52
PMID: 16990761
-
Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung.
In Vivo. 2001 Mar-Apr;15(2):175-80
PMID: 11317524
-
Microtubule-dependent matrix metalloproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion.
Cancer Res. 2004 Dec 15;64(24):8924-31
PMID: 15604254
-
Efficacy and safety of a monoclonal antibody recognizing interleukin-8 in COPD: a pilot study.
Chest. 2004 Sep;126(3):926-34
PMID: 15364775
-
A phase II study of thalidomide in patients with brain metastases from malignant melanoma.
Acta Oncol. 2008;47(8):1526-30
PMID: 18607876
-
Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer.
J Clin Oncol. 1998 Jun;16(6):2150-6
PMID: 9626215
-
Pathology of malignant melanoma.
Surg Clin North Am. 1996 Dec;76(6):1223-55
PMID: 8977548
-
Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma: a phase II Cytokine Working Group study.
Cancer. 2008 Oct 15;113(8):2139-45
PMID: 18792064
-
Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma.
BMC Med Genet. 2007 Mar 08;8:10
PMID: 17346338
-
In vivo therapy of malignant melanoma by means of antagonists of alphav integrins.
Int J Cancer. 2000 Sep 1;87(5):716-23
PMID: 10925366
-
Erlotinib and bevacizumab have synergistic activity against melanoma.
Clin Cancer Res. 2009 May 15;15(10):3495-502
PMID: 19447871
-
Integrin signaling in malignant melanoma.
Cancer Metastasis Rev. 2005 Jun;24(2):195-222
PMID: 15986132
-
Matrix metalloproteinases in human melanoma.
J Invest Dermatol. 2000 Sep;115(3):337-44
PMID: 10951266
-
Bioimmunotherapy for melanoma using fully human antibodies targeting MCAM/MUC18 and IL-8.
Pigment Cell Res. 2006 Oct;19(5):395-405
PMID: 16965268
-
Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1.
Biochim Biophys Acta. 1997 May 27;1356(3):271-80
PMID: 9194570
-
Novel biomarkers in malignant melanoma.
Clin Chim Acta. 2006 May;367(1-2):28-35
PMID: 16480699
-
Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas.
Br J Cancer. 1999 May;80(5-6):733-43
PMID: 10360651
-
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma.
Ann Surg Oncol. 2007 Aug;14(8):2367-76
PMID: 17534686
-
A review of tissue inhibitor of metalloproteinases-3 (TIMP-3) and experimental analysis of its effect on primary tumor growth.
Biochem Cell Biol. 1996;74(6):853-62
PMID: 9164653
-
Phase II trial of pegylated interferon and thalidomide in malignant metastatic melanoma.
Anticancer Drugs. 2007 Nov;18(10):1221-6
PMID: 17893524
-
Selective induction of interleukin-8 expression in metastatic melanoma cells by transforming growth factor-beta 1.
Cytokine. 2005 Aug 7;31(3):241-9
PMID: 15975819
-
Extracellular matrix proteases - cytokine regulation role in cancer and pregnancy.
Front Biosci (Landmark Ed). 2009 Jan 01;14:1571-88
PMID: 19273147
-
Enhanced expression of vascular endothelial growth factor in metastatic melanoma.
Br J Cancer. 1997;76(7):930-4
PMID: 9328154
-
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
J Clin Oncol. 2001 Jan 15;19(2):584-92
PMID: 11208854
-
Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials.
Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):177-203
PMID: 12784996
-
Role of interleukin-8 in tumor growth and metastasis of human melanoma.
Pathobiology. 1999;67(1):12-8
PMID: 9873223
-
Expression and activation of matrix metalloproteinase-2 (MMP-2) and its co-localization with membrane-type 1 matrix metalloproteinase (MT1-MMP) correlate with melanoma progression.
J Pathol. 2000 Jul;191(3):245-56
PMID: 10878545
-
Microvascular density, vascular endothelial growth factor immunoreactivity in tumor cells, vessel diameter and intussusceptive microvascular growth in primary melanoma.
Oncol Rep. 2005 Jul;14(1):81-4
PMID: 15944771
-
Matrix metalloproteinases in tumor progression: focus on basal and squamous cell skin cancer.
Exp Dermatol. 2003 Apr;12(2):109-25
PMID: 12702139
-
Intracameral bevacizumab in the treatment of neovascular glaucoma and exudative retinal detachment after brachytherapy in choroidal melanoma.
Can J Ophthalmol. 2009 Feb;44(1):106-7
PMID: 19169330
-
Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.
Chemotherapy. 2009;55(4):221-7
PMID: 19451711
-
Neovascularisation, expression of fibroblast growth factor-2, and mast cells with tryptase activity increase simultaneously with pathological progression in human malignant melanoma.
Eur J Cancer. 2003 Mar;39(5):666-74
PMID: 12628847
-
Different roles for plasminogen activators and metalloproteinases in melanoma metastasis.
Curr Top Microbiol Immunol. 1996;213 ( Pt 1):65-80
PMID: 8814995
-
Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?
Biochim Biophys Acta. 2004 Mar 4;1654(1):79-94
PMID: 14984769
-
Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy.
Anticancer Res. 2004 May-Jun;24(3a):1759-63
PMID: 15274352
-
Phase I trial of a novel matrix metalloproteinase inhibitor batimastat (BB-94) in patients with advanced cancer.
Invest New Drugs. 1996;14(2):193-202
PMID: 8913840
-
Expression and localization of placenta growth factor and PlGF receptors in human meningiomas.
J Pathol. 1999 Sep;189(1):66-71
PMID: 10451490
-
Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
Cancer. 2007 Nov 15;110(10):2269-75
PMID: 17932881
-
The human melanoma associated protein melanotransferrin promotes endothelial cell migration and angiogenesis in vivo.
Eur J Cell Biol. 2002 Nov;81(11):599-607
PMID: 12494997
-
Phase II study of marimastat (BB-2516) in malignant melanoma: a clinical and tumor biopsy study of the National Cancer Institute of Canada Clinical Trials Group.
Invest New Drugs. 2002 Nov;20(4):431-7
PMID: 12448662
-
A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
J Immunother. 2009 Jan;32(1):79-85
PMID: 19307996
-
Vascularity in cutaneous melanoma detected by Doppler sonography and histology: correlation with tumour behaviour.
Br J Cancer. 1989 Jan;59(1):89-91
PMID: 2667611
-
Thalidomide in cancer.
Biomed Pharmacother. 2002 Feb;56(1):4-12
PMID: 11905508
-
Temozolomide for the treatment of metastatic melanoma: a systematic review.
Oncologist. 2007 Sep;12(9):1114-23
PMID: 17914081
-
Antiangiogenesis therapy might have the unintended effect of promoting tumor metastasis by increasing an alternative circulatory system.
Med Hypotheses. 2010 Feb;74(2):360-1
PMID: 19744799
-
Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma.
Ann Surg. 1970 Nov;172(5):902-8
PMID: 5477666
-
Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase.
J Cutan Pathol. 1997 Apr;24(4):212-8
PMID: 9138111
-
Angiogenic and vascular modulation by extracellular matrix cleavage products.
Curr Pharm Des. 2009;15(4):389-410
PMID: 19199966
-
The role of the vascular phase in solid tumor growth: a historical review.
Neoplasia. 1999 Oct;1(4):293-302
PMID: 10935483
-
Plasminogen activation in melanocytic neoplasia.
Cancer Res. 1994 Aug 15;54(16):4547-52
PMID: 8044805
-
Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Clin Cancer Res. 2003 May;9(5):1648-55
PMID: 12738717
-
Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4048-54
PMID: 15217937
-
Melanocyte tumor progression is associated with changes in angiogenesis and expression of the 67-kilodalton laminin receptor.
Cancer. 1993 Jul 15;72(2):455-61
PMID: 7686442
-
Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A.
Cancer. 2009 Jan 1;115(1):119-27
PMID: 19090009
-
The placenta growth factor in skin angiogenesis.
J Dermatol Sci. 2006 Jan;41(1):11-9
PMID: 16216466
-
Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma.
Blood. 1999 May 1;93(9):3064-73
PMID: 10216103
-
Modulation of metastatic potential by cell surface urokinase of murine melanoma cells.
Cancer Res. 1988 Mar 1;48(5):1270-8
PMID: 2963689
-
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis.
Melanoma Res. 1997 Aug;7 Suppl 2:S19-26
PMID: 9578413
-
The prognostic significance of tumor vascularity in intermediate-thickness (0.76-4.0 mm thick) skin melanoma. A quantitative histologic study.
Am J Pathol. 1988 Nov;133(2):419-23
PMID: 3189515
-
The anti-cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions.
Microvasc Res. 2009 Mar;77(2):78-86
PMID: 18805433
-
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer Chemother Pharmacol. 2007 Feb;59(2):165-74
PMID: 16736151
-
Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.
J Clin Oncol. 2009 Nov 1;27(31):5287-97
PMID: 19738110